Canada markets close in 5 hours 1 minute

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.54-0.01 (-0.18%)
As of 10:55AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close5.55
Open5.52
Bid5.56 x 1000
Ask5.58 x 800
Day's Range5.49 - 5.65
52 Week Range3.96 - 24.28
Volume20,098
Avg. Volume307,062
Market Cap326.922M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

    CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com.

  • GlobeNewswire

    Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

    CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president. “Phillip has been instrumental in building a holistic strate

  • GlobeNewswire

    Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

    Cash balance of $312.2M expected to fund operations into 2025CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progre